You cannot apply for this job anymore (deadline was 30 Aug 2018).
Browse the current job offers or choose an item in the top navigation above.
The ideal candidate holds a PhD in tumor biology or immunology, with a strong publication record. The candidate should be experienced in molecular biology, measurement of immune responses, primary cell cultures, and in vivo mouse models.
As the candidate will integrate a multidisciplinary team, excellent communication and organisation skills are required.
We offer a full-time position for 1 year in an international working environment. The salary - depending on previous qualifications and experience - ranges from €3,175 and €4,166 (scale 10 Collective Labour Agreement Dutch Universities) gross per month for a full-time employment.
Salaries are supplemented with a holiday bonus of 8% and a year-end allowance of 8.3% per year. In addition, Utrecht University offers excellent secondary conditions, including an attractive retirement scheme, (partly paid) parental leave and flexible employment conditions (multiple choice model). Here you'll find more information about working at Utrecht University.
A better future for everyone. This ambition motivates our scientists in executing their leading research and inspiring teaching. At Utrecht University, the various disciplines collaborate intensively towards major societal themes. Our focus is on Dynamics of Youth, Institutions for Open Societies, Life Sciences and Sustainability.
The Faculty of Science consists of six departments: Biology, Pharmaceutical Sciences, Information and Computing Sciences, Physics and Astronomy, Chemistry and Mathematics. The Faculty is home to 5,600 students and nearly 1,500 staff and is internationally renowned for the quality of its research. The Faculty's academic programmes reflect developments in today's society. Read the overall impression 2016 of the Faculty of Science.
Our “Molecular Targeted Therapies” group is mainly focused on rendering current therapies more selective. In particular, we have been developing a new approach for photodynamic therapy (PDT), making it more selective to cancer cells by using nanobodies. Although applied in some hospitals, PDT still is underutilized in the clinic, mainly because of the limited selectivity of the treatment, which employs hydrophobic photosensitizers that can interact with all cell types. Nanobodies are the smallest naturally derived antibody fragments derived from heavy chain antibodies that exist in animals from the camelidae family, and we have demonstrated nanobody-targeted PDT can indeed kill cancer cells locally and selectively.
PDT has been described to induce an acute inflammation, which can trigger an antitumor immune response, thus we are seeking a postdoctoral researcher to investigate the responses triggered by nanobody-targeted PDT.
We like to make it easy for you, sign in for these and other useful features: